{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:00:25Z","timestamp":1775134825557,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008466","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000}}],"reference-count":78,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>The fate of orally inhaled drugs is determined by pulmonary pharmacokinetic processes such as particle deposition, pulmonary drug dissolution, and mucociliary clearance. Even though each single process has been systematically investigated, a quantitative understanding on the interaction of processes remains limited and therefore identifying optimal drug and formulation characteristics for orally inhaled drugs is still challenging. To investigate this complex interplay, the pulmonary processes can be integrated into mathematical models. However, existing modeling attempts considerably simplify these processes or are not systematically evaluated against (clinical) data. In this work, we developed a mathematical framework based on physiologically-structured population equations to integrate all relevant pulmonary processes mechanistically. A tailored numerical resolution strategy was chosen and the mechanistic model was evaluated systematically against data from different clinical studies. Without adapting the mechanistic model or estimating kinetic parameters based on individual study data, the developed model was able to predict simultaneously (i) lung retention profiles of inhaled insoluble particles, (ii) particle size-dependent pharmacokinetics of inhaled monodisperse particles, (iii) pharmacokinetic differences between inhaled fluticasone propionate and budesonide, as well as (iv) pharmacokinetic differences between healthy volunteers and asthmatic patients. Finally, to identify the most impactful optimization criteria for orally inhaled drugs, the developed mechanistic model was applied to investigate the impact of input parameters on both the pulmonary and systemic exposure. Interestingly, the solubility of the inhaled drug did not have any relevant impact on the local and systemic pharmacokinetics. Instead, the pulmonary dissolution rate, the particle size, the tissue affinity, and the systemic clearance were the most impactful potential optimization parameters. In the future, the developed prediction framework should be considered a powerful tool for identifying optimal drug and formulation characteristics.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1008466","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T19:48:18Z","timestamp":1608061698000},"page":"e1008466","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4000-6525","authenticated-orcid":true,"given":"Niklas","family":"Hartung","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7000-9308","authenticated-orcid":true,"given":"Jens Markus","family":"Borghardt","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"issue":"9","key":"pcbi.1008466.ref001","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archinte.159.9.941","article-title":"Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis","volume":"159","author":"BJ Lipworth","year":"1999","journal-title":"Arch Intern Med"},{"key":"pcbi.1008466.ref002","doi-asserted-by":"crossref","first-page":"2732017","DOI":"10.1155\/2018\/2732017","article-title":"Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes","volume":"2018","author":"JM Borghardt","year":"2018","journal-title":"Can Respir J"},{"issue":"1","key":"pcbi.1008466.ref003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00315143","article-title":"Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover","volume":"40","author":"BH Jennings","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"pcbi.1008466.ref004","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy For the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.; 2015."},{"key":"pcbi.1008466.ref005","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention.; 2016."},{"issue":"4","key":"pcbi.1008466.ref006","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.addr.2011.05.009","article-title":"In silico models of aerosol delivery to the respiratory tract\u2014development and applications","volume":"64","author":"PW Longest","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"pcbi.1008466.ref007","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","article-title":"Deposition of particles in the human respiratory tract in the size range 0.005-15 \u03bcm","volume":"17","author":"J Heyder","year":"1986","journal-title":"Journal of Aerosol Science"},{"issue":"4","key":"pcbi.1008466.ref008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/jamp.2011.0899","article-title":"Understanding penetration index measurements and regional lung targeting","volume":"25","author":"AR Clark","year":"2012","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"2","key":"pcbi.1008466.ref009","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/toxsci\/kfg075","article-title":"The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs","volume":"73","author":"W Hofmann","year":"2003","journal-title":"Toxicol Sci"},{"issue":"1","key":"pcbi.1008466.ref010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/089426804322994488","article-title":"Stochastic model of particle clearance in human bronchial airways","volume":"17","author":"W Hofmann","year":"2004","journal-title":"J Aerosol Med"},{"issue":"1","key":"pcbi.1008466.ref011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"JS Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"pcbi.1008466.ref012","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1208\/s12248-015-9760-6","article-title":"Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs","volume":"17","author":"JM Borghardt","year":"2015","journal-title":"AAPS J"},{"issue":"5","key":"pcbi.1008466.ref013","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(13)70072-9","article-title":"Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges","volume":"1","author":"CA Ruge","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"6","key":"pcbi.1008466.ref014","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"NR Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pcbi.1008466.ref015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1208\/s12248-012-9420-z","article-title":"A pharmacokinetic simulation tool for inhaled corticosteroids","volume":"15","author":"B Weber","year":"2013","journal-title":"AAPS J"},{"key":"pcbi.1008466.ref016","article-title":"Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model","author":"A Raut","year":"2019","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"pcbi.1008466.ref017","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bcp.12780","article-title":"Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach","volume":"81","author":"JM Borghardt","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pcbi.1008466.ref018","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bcp.12118","article-title":"Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach","volume":"76","author":"C Bartels","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pcbi.1008466.ref019","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1208\/s12248-016-0042-8","article-title":"Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices","volume":"19","author":"J Melin","year":"2017","journal-title":"AAPS J"},{"issue":"10","key":"pcbi.1008466.ref020","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/psp4.12344","article-title":"A Partial Differential Equation Approach to Inhalation Physiologically Based Pharmacokinetic Modeling","volume":"7","author":"E Boger","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"pcbi.1008466.ref021","unstructured":"Applied Research Associates. Multiple-path dosimetry model version 2.11; 2009. Available from: https:\/\/www.ara.com\/products\/multiple-path-particle-dosimetry-model-mppd-v-211."},{"issue":"1","key":"pcbi.1008466.ref022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2332\/allergolint.11-OA-0332","article-title":"In vitro evaluation of dry powder inhaler devices of corticosteroid preparations","volume":"61","author":"G Tamura","year":"2012","journal-title":"Allergol Int"},{"issue":"3","key":"pcbi.1008466.ref023","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1164\/ajrccm.155.3.9117024","article-title":"Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease","volume":"155","author":"CS Kim","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pcbi.1008466.ref024","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/jamp.2011.0916","article-title":"Aerosol deposition in health and disease","volume":"25","author":"C Darquenne","year":"2012","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"12","key":"pcbi.1008466.ref025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/rccm.200410-1414OC","article-title":"Regional lung deposition and bronchodilator response as a function of \u03b22-agonist particle size","volume":"172","author":"OS Usmani","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"pcbi.1008466.ref026","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/01902140802093196","article-title":"Effect of particle size on slow particle clearance from the bronchial tree","volume":"34","author":"JR Smith","year":"2008","journal-title":"Exp Lung Res"},{"key":"pcbi.1008466.ref027","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/ja02086a003","article-title":"The rate of solution of solid substances in their own solutions","volume":"19","author":"AA Noyes","year":"1897","journal-title":"J Am Chem Soc"},{"key":"pcbi.1008466.ref028","volume-title":"Aerosol technology: Properties, behavior, and measurement of airborne particles","author":"WC Hinds","year":"1999"},{"issue":"2","key":"pcbi.1008466.ref029","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"SI Rennard","year":"1986","journal-title":"J Appl Physiol"},{"issue":"1","key":"pcbi.1008466.ref030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0034-5687(73)90088-1","article-title":"Chemical analysis of the lung alveolar surfactant obtained by alveolar micropuncture","volume":"19","author":"R Reifenrath","year":"1973","journal-title":"Respir Physiol"},{"key":"pcbi.1008466.ref031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000239867","article-title":"The tracheal fluid in the fetal lamb","volume":"5","author":"FH Adams","year":"1963","journal-title":"Biol Neonat"},{"key":"pcbi.1008466.ref032","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-13159-6","volume-title":"The Dynamics of Physiologically Structure Populations","author":"JAJ Metz","year":"1986"},{"issue":"4","key":"pcbi.1008466.ref033","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/psp4.12074","article-title":"Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs","volume":"5","author":"E Boger","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"pcbi.1008466.ref034","first-page":"713","volume-title":"Handbook of Numerical Analysis","author":"R Eymard","year":"2000"},{"key":"pcbi.1008466.ref035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1147\/rd.112.0215","article-title":"On the Partial Difference Equations of Mathematical Physics","volume":"11","author":"R Courant","year":"1967","journal-title":"IBM Journal"},{"key":"pcbi.1008466.ref036","doi-asserted-by":"crossref","DOI":"10.1002\/0470868279","volume-title":"Numerical Methods for Ordinary Differential Equations","author":"JC Butcher","year":"2003"},{"key":"pcbi.1008466.ref037","volume-title":"MATLAB. version 9.5 (R2018b)","year":"2018"},{"key":"pcbi.1008466.ref038","first-page":"155","volume-title":"Respiratory Drug Delivery 2014","author":"OS Usmani","year":"2014"},{"issue":"6","key":"pcbi.1008466.ref039","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2125.1996.36110.x","article-title":"Pharmacokinetics of intravenous fluticasone propionate in healthy subjects","volume":"41","author":"AE Mackie","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"pcbi.1008466.ref040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/00912700122012913","article-title":"Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as diskus or turbohaler dry-powder inhalers to healthy subjects","volume":"41","author":"H M\u00f6llmann","year":"2001","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"pcbi.1008466.ref041","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thorax.58.3.258","article-title":"Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects","volume":"58","author":"TW Harrison","year":"2003","journal-title":"Thorax"},{"key":"pcbi.1008466.ref042","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fphys.2012.00146","article-title":"Why Do We have to Move Fluid to be Able to Breathe?","volume":"3","author":"M Fronius","year":"2012","journal-title":"Front Physiol"},{"issue":"27-28","key":"pcbi.1008466.ref043","first-page":"375","article-title":"What makes a good lung?","volume":"139","author":"ER Weibel","year":"2009","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"pcbi.1008466.ref044","first-page":"605","article-title":"Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs","volume":"4","author":"L Gaohua","year":"2015","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"4","key":"pcbi.1008466.ref045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"RP Brown","year":"1997","journal-title":"Toxicology and Industrial Health"},{"issue":"5","key":"pcbi.1008466.ref046","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/bdd.2510140511","article-title":"Relationship between lung tissue and blood plasma concentrations of inhaled budesonide","volume":"14","author":"JMM Van den Bosch","year":"1993","journal-title":"Biopharmaceutics and Drug Disposition"},{"issue":"6","key":"pcbi.1008466.ref047","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/jps.10151","article-title":"Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3)","volume":"91","author":"G Borchard","year":"2002","journal-title":"J Pharm Sci"},{"key":"pcbi.1008466.ref048","unstructured":"Flexhaler label; 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021949s003lbl.pdf."},{"issue":"4 Pt 2","key":"pcbi.1008466.ref049","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0091-6749(99)70059-X","article-title":"Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid","volume":"104","author":"SJ Szefler","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"pcbi.1008466.ref050","article-title":"Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery","volume":"11","author":"Y Cui","year":"2019","journal-title":"Pharmaceutics"},{"issue":"2","key":"pcbi.1008466.ref051","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/jps.24575","article-title":"Development of a Novel Lung Slice Methodology for Profiling of Inhaled Compounds","volume":"105","author":"E B\u00e4ckstr\u00f6m","year":"2016","journal-title":"J Pharm Sci"},{"issue":"8","key":"pcbi.1008466.ref052","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/acs.molpharmaceut.5b00221","article-title":"Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant","volume":"12","author":"M Rohrschneider","year":"2015","journal-title":"Mol Pharm"},{"key":"pcbi.1008466.ref053","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0092-8240(80)80060-7","article-title":"Models of Human Lung Airways and their Application to inhaled Particle Deposition","volume":"42","author":"HS Yeh","year":"1980","journal-title":"Bull Math Biol"},{"key":"pcbi.1008466.ref054","unstructured":"Advair Diskus label; 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/21077_Advair%20Diskus_prntlbl.pdf."},{"key":"pcbi.1008466.ref055","unstructured":"Pulmicort Turbohaler label; 1998. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20441-S002_Pulmicort_prntlbl.pdf."},{"issue":"4","key":"pcbi.1008466.ref056","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1089\/jamp.2015.1253","article-title":"Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions","volume":"29","author":"M Caniga","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"pcbi.1008466.ref057","unstructured":"Cabal, A and Jajamovich, G and Mehta, K and Guo, P and Przekwas, A. In-Silico Lung Modeling Platform for Inhaled Drug Delivery.; 2016. Available from: https:\/\/aerosol-soc.com\/abstracts\/silico-lung-modeling-platform-inhaled-drug-delivery\/."},{"key":"pcbi.1008466.ref058","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/00039896.1963.10663361","article-title":"Phagocytosis, mucous flow, and ciliary action","volume":"6","author":"AC Hilding","year":"1963","journal-title":"Arch Environ Health"},{"issue":"Suppl. 111","key":"pcbi.1008466.ref059","first-page":"21","article-title":"Pulmonary airway defense mechanisms: an appreciation of integrated mucociliary activity","volume":"61","author":"A van As","year":"1980","journal-title":"Eur J Respir Dis"},{"issue":"3","key":"pcbi.1008466.ref060","first-page":"TE01","article-title":"Recognition of Small Airways Obstruction in Asthma and COPD\u2014The Road Less Travelled","volume":"11","author":"D Deepak","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"pcbi.1008466.ref061","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.13251","article-title":"Pathophysiology of severe asthma: We\u2019ve only just started","volume":"23","author":"GG King","year":"2018","journal-title":"Respirology"},{"issue":"3","key":"pcbi.1008466.ref062","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1513\/pats.200808-091RM","article-title":"Physiologic dysfunction of the asthmatic lung: what\u2019s going on down there, anyway?","volume":"6","author":"CG Irvin","year":"2009","journal-title":"Proc Am Thorac Soc"},{"issue":"3","key":"pcbi.1008466.ref063","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00441-016-2566-8","article-title":"Airway remodeling in asthma: what really matters","volume":"367","author":"H Fehrenbach","year":"2017","journal-title":"Cell Tissue Res"},{"issue":"8","key":"pcbi.1008466.ref064","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200443080-00004","article-title":"Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacokinetics","volume":"43","author":"M Sakagami","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"pcbi.1008466.ref065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5173(99)00295-1","article-title":"Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations","volume":"192","author":"Z Shen","year":"1999","journal-title":"Int J Pharm"},{"key":"pcbi.1008466.ref066","volume-title":"vol. 24 of Annals of the ICRP","author":"Protection International Commission on Radiological","year":"1994"},{"key":"pcbi.1008466.ref067","unstructured":"Cuddihy RG, Fisher GL, Kanapilly GM, Moss OR, Phalen RF, Schlesinger RB, et al. Report No. 125\u2014Deposition, Retention and Dosimetry of Inhaled Radioactive Substances. NCRP; 1997."},{"issue":"11","key":"pcbi.1008466.ref068","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1016\/j.xphs.2016.08.014","article-title":"Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices","volume":"105","author":"E B\u00e4ckstr\u00f6m","year":"2016","journal-title":"J Pharm Sci"},{"issue":"4","key":"pcbi.1008466.ref069","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/ml4005232","article-title":"Discovery of AZD3199, An Inhaled Ultralong Acting \u03b22 Receptor Agonist with Rapid Onset of Action","volume":"5","author":"MJ Stocks","year":"2014","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"pcbi.1008466.ref070","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/j.1552-4604.1997.tb04262.x","article-title":"Pharmacokinetic\/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model","volume":"37","author":"G Hochhaus","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"pcbi.1008466.ref071","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.119.257311","article-title":"Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase \u03b4 Inhibitor","volume":"369","author":"M Begg","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"pcbi.1008466.ref072","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0378-5173(99)00341-5","article-title":"Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler","volume":"193","author":"L Borgstr\u00f6m","year":"2000","journal-title":"Int J Pharm"},{"issue":"3","key":"pcbi.1008466.ref073","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bcp.12999","article-title":"Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation","volume":"82","author":"JM Borghardt","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"pcbi.1008466.ref074","first-page":"57","article-title":"Effects of various inhalation modes on the deposition of radioactive pressurized aerosols","volume":"119","author":"SP Newman","year":"1982","journal-title":"Eur J Respir Dis Suppl"},{"issue":"4","key":"pcbi.1008466.ref075","first-page":"763","article-title":"Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique","volume":"3","author":"P Brand","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"pcbi.1008466.ref076","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1124\/jpet.114.221226","article-title":"A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: toward an improved understanding of lung pharmacokinetic\/pharmacodynamic relationships","volume":"353","author":"E Boger","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-2","key":"pcbi.1008466.ref077","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-3659(99)00230-8","article-title":"Drug solubilization in lung surfactant","volume":"65","author":"TS Wiedmann","year":"2000","journal-title":"J Control Release"},{"issue":"2","key":"pcbi.1008466.ref078","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2008.09.012","article-title":"Micro- and macrorheology of mucus","volume":"61","author":"SK Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008466","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T19:15:45Z","timestamp":1609269345000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008466"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":78,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008466","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1008466","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}